Product Overview
【Generic Name】
Levoamlodipine Besylate Tablets
【Drug Name】
Jingruixin Levoamlodipine Besylate Tablets
【Main Ingredients】
The active ingredient of this product is levamlodipine besylate. [Functions and Indications] (1) Hypertension. (2) Angina pectoris.
【Usage and Dosage】
(1) The initial dose for the treatment of hypertension and angina pectoris is 2.5 mg once a day; the dose can be increased according to the patient's clinical response, up to a maximum of 5 mg once a day. (2) No dose adjustment is required when this product is used in combination with thiazide diuretics, beta-receptor blockers and angiotensin-converting enzyme inhibitors.
【Adverse Reactions】
This product is well tolerated by patients. (1) Less common side effects include headache, edema, fatigue, insomnia, heart and abdominal pain, flushing, palpitations and dizziness; (2) Very rare side effects include itching, rash, dyspnea, weakness, muscle cramps and indigestion; (3) Similar to other calcium channel blockers, there are very few reports of adverse reactions such as myocardial infarction and chest pain, and these adverse reactions cannot be clearly distinguished from the patient's underlying disease; (4) No abnormal laboratory test parameters related to this product have been found.
【Precautions】
1. Use in patients with impaired liver function. As with all other calcium channel blockers, this product should be used with extreme caution in patients with impaired liver function. 2. Use in patients with renal failure. Patients with impaired renal function can use normal doses. 3. This product is not dialyzed.
【Interactions】
(1) This product is safe to be used in combination with the following drugs: thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, nonsteroidal anti-inflammatory drugs, antibiotics and oral hypoglycemic drugs.
(2) In healthy volunteers, the combination of this product with digoxin did not change the blood concentration or renal clearance of digoxin; when combined with cimetidine, the pharmacokinetics of this product did not change.
(3) In vitro study data showed that this product had no effect on the plasma protein binding rate of digoxin, phenytoin, warfarin or indomethacin.
(4) In healthy male volunteers, the combination of this product with warfarin did not affect the changes in prothrombin time caused by warfarin.
【Specifications】
20 tablets/box
【Approval Number】
National Medicine Standard H20093801
【Manufacturer】
North China Pharmaceutical Co., Ltd.
